HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could radiation replace the knife? new trial tests surgery-free breast cancer treatment
Disease control Not yet recruitingThis study is testing whether some people with early-stage breast cancer can safely skip surgery after chemotherapy and instead use only radiation. It includes 84 adults with HER2-positive or triple-negative breast cancer who have responded well to initial chemo. The goal is to s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for breast cancer patients: extra targeted drug may clear remaining tumors
Disease control Not yet recruitingThis study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goa…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
PET scans could guide smarter breast cancer therapy
Disease control Not yet recruitingThis study tests whether a special PET scan (HER2-PET) can help doctors personalize treatment for early-stage HER2-positive breast cancer. After two cycles of standard therapy, the scan results will determine if patients need stronger or milder treatment. The goal is to improve t…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough breast cancers: smart switch to targeted drug combo
Disease control Not yet recruitingThis study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard therapy, those whose tumors shrink less than 40% will switch to a new drug combination (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is t…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
AI takes on breast cancer: could a computer pick better treatment than standard care?
Disease control Not yet recruitingThis study tests whether an artificial intelligence (AI) model can choose the best combination of targeted drugs for women with HER2-positive breast cancer before surgery. About 280 women with early or locally advanced breast cancer will be randomly assigned to either AI-guided t…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New triple-drug combo aims to keep advanced breast cancer in check
Disease control Not yet recruitingThis study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help control HER2-positive advanced breast cancer longer. About 42 adults with advanced disease will receive this combination as maintenance therapy after initial treatment. The ma…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy targets breast cancer brain metastases
Disease control Not yet recruitingThis early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for hard-to-treat breast cancer: experimental drug takes on standard therapy
Disease control Not yet recruitingThis study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line treatment trastuzumab. The goal is to see which approach better delays cance…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for HER2+ breast cancer patients who stopped responding to standard therapy
Disease control Not yet recruitingThis study tests whether a drug called RC48, combined with chemotherapy, works better than standard treatments for women with advanced HER2-positive breast cancer whose disease has progressed after prior therapy. About 268 participants will be randomly assigned to receive either …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New drug combo aims to shrink HER2 breast tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding an experimental immunotherapy (QL1706) to standard chemotherapy and targeted drugs can better eliminate HER2-positive breast cancer before surgery. About 188 people with early or locally advanced disease will be randomly assigned to receive…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a pill prevent dangerous platelet drops during breast cancer treatment?
Disease control Not yet recruitingThis study tests whether herombopag tablets can prevent low platelet counts in 45 women with HER2-positive breast cancer who are receiving T-DM1 therapy. T-DM1 is effective but often causes low platelets, especially in Asian patients, which can force treatment delays or dose redu…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Zhenzhen Liu • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy aims to keep advanced breast cancer in check longer
Disease control Not yet recruitingThis phase II trial tests whether a maintenance therapy of trastuzumab plus either pyrotinib or dalpiciclib and endocrine therapy can delay disease progression in people with HER2-positive advanced breast cancer. After an initial treatment with trastuzumab rezetecan, 288 particip…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 18:20 UTC
-
New drug targets breast cancer in the brain
Disease control Not yet recruitingThis study tests a drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain or the lining of the brain and spinal cord. The drug is given either through a vein or directly into the spinal fluid. The goal is to see if it is safe and can shrin…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
New hope for brain metastases: Dual-Drug attack on HER2 breast cancer
Disease control Not yet recruitingThis Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 26, 2026 12:35 UTC
-
Could a simple machine take the sting out of breast cancer injections?
Symptom relief Not yet recruitingThis study compares two ways of giving a large-volume subcutaneous injection of targeted therapy (pertuzumab and trastuzumab) to 40 women with HER2-positive breast cancer. Each patient will receive one injection by a nurse using a stopwatch to mimic a steady speed, and another in…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Which Follow-Up treatment works best for HER2+ breast cancer? large study aims to find out
Knowledge-focused Not yet recruitingThis study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Hebei Medical University Fourth Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Gut bacteria could be key to stopping cancer Drug's diarrhea side effect
Knowledge-focused Not yet recruitingThis study looks at why some breast cancer patients get diarrhea from the drug pyrotinib while others don't. Researchers will compare the gut bacteria of 60 patients who develop diarrhea with those who don't. They hope to find specific bacteria that protect against this side effe…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Hubei Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New study aims to decode HER2+ breast cancer for personalized treatment
Knowledge-focused Not yet recruitingThis study will enroll over 1,000 women with HER2-positive breast cancer to analyze the molecular characteristics and subtypes of their tumors. Participants will receive standard pre-surgery treatment with trastuzumab, pertuzumab, and chemotherapy. The goal is to identify which s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Shandong Cancer Hospital and Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC